Poseida Therapeutics Ownership
| PSTX Stock | USD 9.31 0.02 0.21% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 97 M | Current Value 98.2 M | Avarage Shares Outstanding 68.5 M | Quarterly Volatility 19.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Poseida |
Poseida Stock Ownership Analysis
About 28.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings (P/E) ratio of 214.0. Poseida Therapeutics recorded a loss per share of 0.63. The entity last dividend was issued on the June 23, 1992. The firm had 3:1 split on the April 5, 2005. Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company was incorporated in 2014 and is headquartered in San Diego, California. Poseida Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 290 people. To find out more about Poseida Therapeutics contact Kristin Yarema at 858 779 3100 or learn more at https://poseida.com.Besides selling stocks to institutional investors, Poseida Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Poseida Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Poseida Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Poseida Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Poseida Therapeutics Insider Trades History
About 28.0% of Poseida Therapeutics are currently held by insiders. Unlike Poseida Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Poseida Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Poseida Therapeutics' insider trades
Poseida Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Poseida Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Poseida Therapeutics backward and forwards among themselves. Poseida Therapeutics' institutional investor refers to the entity that pools money to purchase Poseida Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 811.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 726.6 K | Millennium Management Llc | 2024-06-30 | 643 K | Charles Schwab Investment Management Inc | 2024-09-30 | 567.1 K | Northern Trust Corp | 2024-09-30 | 565.4 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 563.1 K | Goldman Sachs Group Inc | 2024-06-30 | 501.9 K | Nuveen Asset Management, Llc | 2024-06-30 | 402.9 K | Wellington Management Company Llp | 2024-06-30 | 387.3 K | Fmr Inc | 2024-09-30 | 14.6 M | Pentwater Capital Management Lp | 2024-09-30 | 6 M |
Poseida Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Poseida Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Poseida Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Poseida Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Poseida Therapeutics Outstanding Bonds
Poseida Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Poseida Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Poseida bonds can be classified according to their maturity, which is the date when Poseida Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Poseida Therapeutics Corporate Filings
| 27th of November 2024 Other Reports | ViewVerify | |
8K | 26th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 22nd of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 7th of June 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.